The refinancing and ATM facility underscore persistent cash burn. Watch for ATM issuances post-closing, which will dilute existing shareholders. Monitor preclinical/clinical catalysts to offset dilution; the stock may face near-term pressure as the market prices in the convertible note's discount features and potential registration of warrant shares.
Price Chart
Executive Summary
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warrant for 2.16M shares at $1.1824, while prepaying existing convertible debentures at 103% of principal and terminating the prior ATM agreement. A new ATM facility with Yorkville Securities was also established. This financing, following a recently effective $200M S-3 shelf, signals urgent capital needs and potential dilution, weighing on the stock.
Key Financial Metrics
Key Facts
- $6M promissory note at 10% interest, issued at $5.76M (4% OID), due 12 months from closing
- Warrant to purchase 2,158,274 shares at $1.1824 per share (exercisable 6 months post-closing, 5-year term)
- Prepayment of existing Senior Secured Convertible Debentures at 103% of principal plus accrued interest
- New ATM sales agreement with Yorkville Securities under the effective S-3 shelf (up to $200M)
- S-3/A shelf registration filed April 27, 2026, declared effective April 28, 2026
- Closing expected on or around June 12, 2026, subject to conditions including repayment of existing debt
Financial Impact
$6M principal (4% OID), warrant representing ~4.1% of current shares outstanding (based on 52.6M shares outstanding estimate from market cap $53M at ~$1.01/share)
Risk Factors
- Dilution from warrant exercise and potential conversion of the note (up to 19.99% of outstanding without stockholder approval)
- Note conversion triggers after default (95% of 5-day VWAP or 92% of prior close) could lead to severe dilution if stock declines
- ATM program may be used aggressively, further pressuring share price
- Failure to meet closing conditions (e.g., debt repayment, Nasdaq listing) could disrupt financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-018464 |
| Document: 0001140361-26-018464-index-headers.html | 0001140361-26-018464 |
| Document: 0001140361-26-018464-index.html | 0001140361-26-018464 |
| Document: 0001140361-26-018464.txt | 0001140361-26-018464 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7485 (−149.50%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7485 (+258.31%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7485 (−220.97%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7485 (−191.25%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7485 (−4.61%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7485 (−16.75%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7485 (+22.03%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7485 (−26.62%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7485 (−35.47%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7485 (−43.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access